Features of intestinal microbiota disorders in the development of metabolic disorders in non-alcoholic fatty liver disease

Cover Page

Cite item

Full Text

Abstract

We discussed about the term “intestinal permeability” like as the mucosal barrier – a single structural and functional conception that includes the layer of mucus, the indigenous microbiota and the epithelium of the mucosa in this publication. Information was presented about the role of the microbiota, the composition of intestinal mucus, epithelial cells and proteins of tight junctions which lead to various metabolic diseases. The complex pathogenetic interactions are formed between the intestinal mucosal barrier, metabolic disorders such as non-alcoholic fatty liver disease and cardiovascular diseases. The complex researches and modification of this interactions will allow to create personalized approaches and to prevent of these diseases.

About the authors

M. A. Livzan

Omsk State Medical University

Email: mts-8-90@mail.ru
ORCID iD: 0000-0002-6581-7017

д.м.н., проф., зав. каф. факультетской терапии и гастроэнтерологии, ректор

Russian Federation, Omsk

T. S. Krolevets

Omsk State Medical University

Author for correspondence.
Email: mts-8-90@mail.ru
ORCID iD: 0000-0002-7452-7230

к.м.н., доц. каф. факультетской терапии и гастроэнтерологии

Russian Federation, Omsk

S. I. Mozgovoy

Omsk State Medical University

Email: mts-8-90@mail.ru
ORCID iD: 0000-0001-7200-7082

д.м.н., доц., проф. каф. патологической анатомии

Russian Federation, Omsk

N. A. Nikolaev

Omsk State Medical University

Email: mts-8-90@mail.ru
ORCID iD: 0000-0002-3758-4930

д.м.н., доц. каф. факультетской терапии и гастроэнтерологии

Russian Federation, Omsk

A. V. Nelidova

Omsk State Medical University

Email: mts-8-90@mail.ru
ORCID iD: 0000-0003-0149-6119

к.м.н., доц. каф. пропедевтики внутренних болезней

Russian Federation, Omsk

References

  1. Fialho A, Fialho A, Kochhar G, et al. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci. 2018;63(2):412–21. doi: 10.1007/s10620-017-4828-z.
  2. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3-20. doi: 10.1016/j.jaci.2009.05.038
  3. Wada M, Tamura A, Takahashi N, Tsukita S. Loss of claudins 2 and 15 from mice causes defects in paracellular Na + flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology. 2013;144:369-80. doi: 10.1053/j.gastro.2012.10.035
  4. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-93. doi: 10.1038/35067088
  5. Ulluwishewa D, Anderson RC, McNabb WC, et al. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141:769-76. doi: 10.3945/jn.110.135657
  6. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809. doi: 10.1038/nri2653
  7. Johansson ME, Thomsson KA, Hansson GC. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J Proteome Res. 2009;8:3549-57. doi: 10.1021/pr9002504
  8. Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-20. doi: 10.1126/science.1104816
  9. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-8. doi: 10.1126/science.1110591
  10. Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science. 2008;320:1647-51. doi: 10.1126/science.1155725
  11. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
  12. Rinninella E, Raoul P, Cintoni M, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1):14. doi: 10.3390/microorganisms7010014
  13. Johnston DG, Corr SC. Toll-Like Receptor Signalling and the Control of Intestinal Barrier Function. Methods Mol Biol. 2016;1390:287-300. doi: 10.1007/978-1-4939-3335-8_18
  14. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterology. 2014;14:189. Available at: http://www.biomedcentral.com/1471-230X/14/189
  15. Ahmad R, Rah B, Bastola D, et al. Obesity-induces Organ and Tissue Specific Tight Junction Restructuring and Barrier Deregulation by Claudin Switching. Sci Rep. 2017;7(1):5125. doi: 10.1038/s41598-017-04989-8
  16. Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25:1054-62.e1-e5. doi: 10.1016/j.cmet.2017.04.001
  17. Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019;50:144-58. doi: 10.1111/apt.15314
  18. Duseja A, Acharya SK, Mehta M, et al. High potency multistrain probiotic improves liver histology in nonalcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastro. 2019;6:e000315. doi: 10.1136/ bmjgast-2019-000315
  19. Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of non alcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019;50:144-58. doi: 10.1111/apt.15314
  20. Geurts L, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: Impact on apelin regulation in adipose tissue. Front Microbiol. 2011;2:149. doi: 10.3389/fmicb.2011.00149
  21. Rizzatti G, Lopetuso LR, Gibiino G, et al. Proteobacteria: A common factor in human diseases. Biomed Res Int. 2017;2017:9351507. doi: 10.1155/2017/9351507
  22. Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. 2018;16:171-81. doi: 10.1038/nrmicro.2017.149
  23. Yamashita T. Intestinal Immunity and Gut Microbiota in Atherogenesis. J Atheroscler Thromb. 2017;24:110-9. doi: 10.5551/jat.38265
  24. Al-Obaide MAI, Singh R, Datta P, et al. Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD. J Clin Med. 2017;6(9):1-13. doi: 10.3390/jcm6090086
  25. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June 2012. Available at: http://www.worldgastroenterology.org/NAFLD-NASH.html
  26. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. и др. Неалкогольная жировая болезнь печени с позиций современной медицины: учеб. пособие. М.: Прима Принт, 2020 [Maev IV, Andreev DN, Kucheriavyi IuA, et al. Non-alcoholic fatty liver disease from the standpoint of modern medicine: a tutorial. Moscow: Prima Print, 2020 (In Russ.)].
  27. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis. Hepatology. 2017;65(5):1557-65. doi: 10.1002/hep.29085
  28. Sharma M, Mitnala S, Vishnubhotla RK, et al. The Riddle of Nonalcoholic Fatty Liver Disease: Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-58. doi: 10.1016/j.jceh.2015.02.002
  29. Maev IV, Samsonov AA, Palgova LK, et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020;7(1):e000341. doi: 10.1136/bmjgast-2019-000341
  30. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016;65:1109-23. doi: 10.1016/j.metabol.2016.05.003
  31. Маев И.В., Юренев Г.Л., Миронова Е.М., Юренева-Тхоржевская Т.В. Фенотип ожирения и гастроэзофагеальной рефлюксной болезни в контексте коморбидности у больных с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2019;91(2):126-33 [Maev IV, Yurenev GL, Mironova EM, Yureneva-Thorzhevskaya TV. Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):126-33 (In Russ.)]. doi: 10.26442/00403660.2019.02.000099
  32. Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. Med Clin North Am. 2017;101:129-37. doi: 10.1016/j.mcna.2016.08.009
  33. Artunc F, Schleicher E, Weigert C, et al. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12:721-37. doi: 10.1038/nrneph.2016.145
  34. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21:406-12. doi: 10.1681/ASN.2009080820
  35. Ливзан М.А., Колбина М.В., Матошина И.В. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казанской мед. школы. 2014;1(4):44-8 [Livzan MA, Kolbina MV, Matoshina IV, et al. Hormones adipose tissue and non-alcoholic fatty liver disease at metabolic syndrome. Diary of Kazan Medical School. 2014;1(4):44-8 (In Russ.)]. Available at: https://readera.ru/140125975
  36. Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070-91. doi: 10.3748/wjg.v20.i48.18070
  37. Saxena NK, Anania FA. Anania Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab. 2015;26(3):153-61. doi: 10.1016/j.tem.2015.01.002
  38. Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav. 2014;130:157-69. doi: 10.1016/j.physbeh.2014.04.003
  39. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Экспериментальная и клиническая гастроэнтерология. 2014;108(8):27-33 [Livzan MA, Lapteva IV, Miller TS. Role leptin and leptinresistance to organization non-alcoholic fatty liver disease in persons with obesity and overweight. Eksperimental’naia i klinicheskaia gastroenterologiia. 2014;108(8):27-33 (In Russ.)].
  40. Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10):57-65 [Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. Eksperimental’naia i klinicheskaia gastroenterologiia. 2019;170(10):57-65 (In Russ.)]. doi: 10.31146/1682-8658-ecg-170-10-57-65
  41. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987-95. doi: 10.1038/ni1112
  42. Heidemann J, Domschke W, Kucharzik T, Maaser C. Intestinal microvascular endothelium and immunity in inflammatory bowel disease: a secondline of defense? Infect Immun. 2006;74:5425-32. doi: 10.1128/iai.00248-06
  43. Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol. 2001;166:2018-24.
  44. Shah V, Lyford G, Gores G, Farrugia G. Nitric Oxide in Gastrointestinal health and disease. J Gastroenterology. 2004;126:903-13. doi: 10.1053/j.gastro.2003.11.046
  45. Cibor D, Domagala-Rodacka R, Rodacki T et al. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol. 2016;22(3):1067-77. doi: 10.3748/wjg.v22.i3.1067

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Представление взаимодействий между интестинальным мукозальным барьером, метаболическими нарушениями и ССЗ. Примечание. 1 – белки TJ, 2 – микробиота; PNPLA3 – ген пататин-подобный фосфолипазный домен 3, TM6SF2 – трансмембранный 6 суперсемейства 2 человеческий ген, GCKR – ген, кодирующий белок, регулирующий глюкокиназу, HSD17B13 – ген, кодирующий энзим 17β-гидроксистероиддегидрогеназу типа 13.

Download (715KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies